BCL-2 inhibitor Venetoclax enhances tumor cell susceptibility to CAR-T cells by antagonizing BCL-2-mediated anti-apoptotic signaling and inducing G1-phase cell cycle arrest (27). The gene discussed is BCL2; the disease is neoplasm.